Statins and diabetes

Cardiology Clinics

Volumn 33, Issue 2, 2015, Pages 233-243

  Maki, Kevin C ^a   Dicklin, Mary R ^a   Baum, Seth J ^b  

^a Metabolic Sciences   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Coronary heart disease; Diabetes mellitus; Dyslipidemia; Glucose; Glycemia; High intensity statins; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; LIPID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INCIDENCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HEALTH;

DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLOBAL HEALTH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIPIDS;

EID: 84928792650     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2015.02.004     Document Type: Review

References (44)

1. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
2. Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. Cholesterol Treatment Trialists' (CTT) Collaborators.
3. Taylor R. Banting Memorial Lecture 2012: reversing the twin cycles of type 2 diabetes. Diabet Med 2013, 30:267-275.
4. Ridker P.M., Danielson E., Fonseca F.A., JUPITER Study Group, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359:2195-2207.
5. Ridker P.M., Pradhan A., MacFadyen J.G., et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
6. Rajpathak S.N., Kumbhani D.J., Crandall J., et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
7. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010, 375:735-742.
8. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
9. Waters D.D., Ho J.E., DeMicco D.A., et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. JAm Coll Cardiol 2011, 57:1535-1545.
10. Maki K.C., Ridker P.M., Brown W.V., et al. An assessment by the statin diabetes safety task force: 2014 update. JClin Lipidol 2014, 8:S17-S29.
11. National Center for Chronic Disease Prevention andHealth Promotion. Division of Diabetes Translation. National Diabetes Statistics Report. 2014. Available at:. Accessed February 24, 2015. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
12. International Diabetes Federation. IDF Diabetes Atlas. 6th edition. 2014. Available at: Accessed February 24, 2015. http://www.idf.org/sites/default/files/Atlas-poster-2014_EN.pdf.
13. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. Available at: Accessed November 6, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
14. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
15. Swerdlow D.J., Preiss D., Kuchenbaecker K.B., et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015, 385:351-361.
16. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2014, 63(25 Pt B):2889-2934.
17. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92:152-160.
18. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. NEngl J Med 2005, 352:1425-1435.
19. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
20. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J., Bowman L., et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010, 376:1658-1669.
21. Danaei G., Garcia Rodriquez L.A., Fernandez Cantero O., et al. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013, 36:1236-1240.
22. Corrao G., Ibrahim B., Nicotra F., et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care 2014, 37:2225-2232.
23. Dormuth C.R., Filion K.B., Paterson J.M., et al. Canadian network for observational drug effect studies investigators. Higher potency statins and the risk of new diabetes: multicenter, observational study of administrative databases. BMJ 2014, 348:g3244.
24. Macedo A.F., Taylor F.C., Casas J.P., et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014, 12:51.
25. Gerich J.E. Measurements of renal glucose release. Diabetes 2001, 50:905.
26. DeFronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
27. Lamendola C., Abbasi F., Chu J.W., et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol 2005, 95:189-193.
28. Baker W.L., Talati R., White C.M., et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
29. Abbas A., Milles J., Ramachandran S. Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidemia. Clin Med Insights Endocrinol Diabetes 2012, 5:13-30.
30. Sato H., Carvalho G., Sato T., et al. Statin intake is associated with decreased insulin sensitivity during cardiac surgery. Diabetes Care 2012, 35:2095-2099.
31. Sampson U.K., Linto M.F., Fazio S. Are statins diabetogenic?. Curr Opin Cardiol 2011, 26:342-347.
32. Banach M., Malodobra-Mazur M., Gluba A., et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013, 19:4904-4912.
33. Goldstein M.R., Mascitelli L. Do statins cause diabetes?. Curr Diab Rep 2013, 13:381-390.
34. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
35. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
36. Colhoun H.M., Betteridge D.J., Durrington P.N., CARDS Investigators, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 2004, 364:685-696.
37. Holman R.R., Paul S., Farmer A., Atorvastatin in Factorial with Omega 3 EE90 Risk Reduction in Diabetes Study Group, et al. Atorvastatin in Factorial withOmega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia 2009, 52:50-59.
38. Zhou Y., Yuan Y., Cai R.R., et al. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opin Pharmacother 2013, 14:1575-1584.
39. Astra Zeneca. Clinical briefing document - Endocrine and Metabolic Drugs Advisory Committee meetingforrosuvastatin (Crestor). Available at: Accessed November 5, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM193833.pdf.
40. American Diabetes Association Standards of medical care in diabetes - 2014. Diabetes Care 2014, 37(Suppl 1):S14-S80.
41. American Diabetes Association Standards of medical care in diabetes - 2015. Diabetes Care 2015, 38(Suppl 1):S1-S90.
42. Katsiki N., Theocharidou E., Karagiannis A., et al. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 2013, 19:3107-3114.
43. Cannon CP on behalf of the IMPROVE IT Investigators. IMPROVE-IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Late-breaking clinical trial abstracts and clinical science special reports abstracts from the American Heart Association's Scientific Sessions 2014. Circulation. 2014;130:2105-2126.
44. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.